Affiliation:
1. Fudan University Shanghai Cancer Center
Abstract
Abstract
PURPOSE
To compare the clinical characteristics, toxicity and efficacy of re-irradiation between locoregional esophageal recurrence within and outside the initial PTV (Planning target volume) after definitive chemoradiotherapy for ESCC (esophageal squamous cell carcinoma).
MATERIALS AND METHODS
Patients receiving re-irradiation for esophageal recurrence three months after definitive chemoradiotherapy for ESCC were retrospectively analyzed. Patients were divided into in- and out-of-PTV recurrence groups depending on the recurrent lesion center within or outside the initial PTV. The clinical characteristics, toxicities and efficacy of re-irradiation were compared between these two groups.
RESULTS
116 eligible patients from June 2009 to October 2019 were analyzed with 68 patients in the in-PTV group and 48 in the out-of-PTV group. The median initial radiation dose was 61.2 Gy in both groups. 39 patients (57.4%) in the in-PTV group and 28 patients (58.3%) in the out-of-PTV group received chemoradiotherapy in salvage treatment, while the others received re-irradiation only. The median re-irradiation doses were 50.4 Gy and 60 Gy in the in- and out-of-PTV groups, respectively. The median survival times were 9.9 months and 31.8 months in the in-PTV and out-of-PTV groups (P < 0.001), respectively, with 2-year local control rates 10.7% and 56.9% (P < 0.001). The rates of esophageal perforation in the in-PTV and out-of-PTV groups were 8.8% and 4.2% during or after re-irradiation, respectively, with esophageal hemorrhage (≥ grade 3) 11.8% and 0%.
CONCLUSION
Patients with out-of-PTV esophageal recurrence are different from in-PTV recurrence with the better safety, radiosensitivity and efficacy of re-irradiation after definitive chemoradiotherapy.
Publisher
Research Square Platform LLC
Reference22 articles.
1. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial;Chen Y;J Clin oncology: official J Am Soc Clin Oncol,2019
2. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85 – 01);Cooper JS;Radiation Therapy Oncology Group Jama,1999
3. INT 0123 (Radiation Therapy Oncology Group 94 – 05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy;Minsky BD;J Clin oncology: official J Am Soc Clin Oncol,2002
4. Cohen C, Tessier W, Gronnier C, Renaud F, Pasquer A, Thereaux J et al. Salvage Surgery for Esophageal Cancer: How to Improve Outcomes? Annals of surgical oncology. 2018;25:1277-86.
5. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone;Chen Y;Dis esophagus: official J Int Soc Dis Esophagus,2014